Article
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood - 15 Mar 2007
Hochhaus Andreas, Kantarjian Hagop M, Baccarani Michele, Lipton Jeffrey H, Apperley Jane F, Druker Brian J, Facon Thierry, Goldberg Stuart L, Cervantes Francisco, Niederwieser Dietger, Silver Richard T, Stone Richard M, Hughes Timothy P, Muller Martin C, Ezzeddine Rana, Countouriotis Athena M, Shah Neil P
Abstract excerpt
Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly problematic, and treatment options for imatinib-resistant or -intolerant CML are limited. Dasatinib, a novel, highly potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, induced cytogenetic responses in a phase 1 study in imatinib-resistant or -intolerant CML and was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.